Clinical trials: Major Depressive Disorder, completed
Major Depressive Disorder, MDD
Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder
The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive extended reality (XR) headset to engage in behavioral activation (BA) for individuals diagnosed with major…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT05525390
- Testing
- Extended Reality-Enhanced Behavioral Activation, Traditional Behavioral Activation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Stanford University
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Alcohol Use Disorder
Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.
The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
- Trial name
- Alaunus (NCT03265808)
- Testing
- allogeneic human mesenchymal stem cells (allo-hMSCs)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Ihsan M Salloum, MD, MPH
Treatment-Resistant Depression, Major Depressive Disorder
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression
An observational-comparative study, without interfering with the treatment, based on an operationalized interview.
- Trial name
- NCT06232291
- Where
- Poland
- Volunteers
- 3 people
- Sponsor
- Medical University of Gdansk
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01305408
- Testing
- Armodafinil
- Where
- 130 sites in United States, Argentina and 12 more
- Volunteers
- 399 people
- Sponsor
- Cephalon
Bipolar Disorder
Evaluation of the Genetics of Bipolar Disorder
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
- Trial name
- NCT00001174
- Where
- United States
- Volunteers
- 4,210 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
The current use of telepsychiatry, or psychiatric care using videoconferencing, is very limited. The present study investigates the use of this method with a depressed Chinese American population in a nursing home.
- Trial name
- NCT00505518
- Testing
- Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India
- Trial name
- NCT04288895
- Testing
- Vortioxetine
- Where
- 24 sites in India
- Volunteers
- 400 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Depression and anxiety disorders are among the most prevalent of all mental disorders, with an estimated annual prevalence of 9.7% and 18.1%…
- Trial name
- NCT04874077
- Where
- 2 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder
The primary aim of the study is to determine whether adjunctive intranasal insulin will exert an antidepressant effect when compared to placebo in adults with major depressive disorder (MDD), insufficiently responsive…
- Trial name
- NCT00570050
- Testing
- Diluent / Insulin, Insulin / Diluent
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Major Depression, Anxiety Disorder
Depression Agency-Based Collaboration
Seniors who receive supportive services face a variety of psychosocial vulnerabilities that put them at risk for depression. One group with very high risk is older adults receiving aging services through Medicaid waiver programs.
- Trial name
- NCT01566318
- Testing
- Problem-Solving Therapy
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Study of Mindfulness-Based Cognitive Therapy
Research aimed at assessing changes in depressogenic thinking and the ability to disengage from depressogenic thinking following Mindfulness-Based Cognitive Therapy
- Trial name
- MBCT (NCT00943033)
- Testing
- Mindfulness-Based Cognitive Therapy
- Volunteers
- 48 people
- Sponsor
- Binghamton University
Major Depressive Disorder
Internet-Based Depression Screening for College Students
This study aims to determine whether using telecommunication tools, specifically web pages containing online screening instruments and real-time video chat, will be an efficient way to implement Major Depressive Disorder…
- Trial name
- NCT01326793
- Testing
- Skype Consultation
- Where
- United States
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection…
- Trial name
- NCT02473289
- Testing
- Sirukumab 50 mg
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 193 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture
This will be a randomized, single blind study of 6 weeks duration involving the use of auricular acupuncture or sham acupuncture in the adjunctive treatment of depression in college students.
- Trial name
- NCT02579343
- Testing
- Auricular Acupuncture
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Florida Gulf Coast University
Major Depressive Disorder
VR-Moodboost; an Innovative Virtual Reality Treatment for Adolescents With Depression
Major depressive disorder (MDD) is a prevalent and disabling mental health condition. A recent meta-analysis shows that across all forms of psychotherapy, only 43% of all depressive patients fully recover from MDD and relapse…
- Trial name
- VR-Moodboost (NCT05486676)
- Testing
- VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Claudi Bockting
Major Depressive Disorder (MDD)
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
- Trial name
- NCT06796868
- Testing
- GW117 Tablets
- Where
- 17 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.